Related Experiment Videos

Ca2+-sensitisers--a promising option to treat heart failure?

Klara Brixius1, Heike Katharina Hoyer, Robert H G Schwinger

  • 1Laboratory of Muscle Research and Molecular Cardiology, Department of Internal Medicine III, University of Cologne, Cologne.

Cardiovascular Drugs and Therapy
|February 3, 2006
PubMed

Insights

New therapies are needed for heart failure patients awaiting transplants. Calcium sensitizers, like pimobendan and levosimendan, improve heart function by directly influencing muscle contraction, offering a vital treatment bridge.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Heart transplantation is limited by donor organ availability, creating a critical need for alternative therapies.
  • Patients with heart failure require treatments to manage symptoms and improve outcomes while awaiting transplantation.
  • Calcium (Ca2+) sensitizers represent a class of drugs that directly modulate cardiac myofilaments and the cross-bridge cycle.

Purpose of the Study:

  • To review the molecular mechanisms of calcium sensitizers.
  • To survey the therapeutic effectiveness of calcium sensitizers in human heart failure.
  • To highlight current clinical applications of calcium sensitizers.

Main Methods:

  • Literature review of studies on calcium sensitizers.
  • Analysis of molecular mechanisms of action for different classes of calcium sensitizers.
  • Evaluation of clinical trial data on pimobendan and levosimendan in heart failure.

Main Results:

  • Calcium sensitizers are classified into three groups based on their molecular actions.
  • Pimobendan and levosimendan are the primary calcium sensitizers currently used in clinical practice.
  • These agents demonstrate therapeutic benefits in managing heart failure symptoms and improving cardiac function.

Conclusions:

  • Calcium sensitizers offer a promising therapeutic strategy for heart failure patients.
  • Understanding their molecular mechanisms is key to optimizing their use.
  • Further research may expand the clinical application of calcium sensitizers in cardiovascular medicine.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.